Kerry E. Jewell

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 07, 2025

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

Journal: The Lancet. Oncology

Published: April 17, 2025

Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.

Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 06, 2025

Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.

Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 10, 2025

Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 30, 2024

Erratum for: Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.

Erratum for: Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.

Journal: Radiology

Published: June 25, 2024

Combination Strategies and Targeted Radionuclide Therapies.

Combination Strategies and Targeted Radionuclide Therapies.

Journal: Seminars in nuclear medicine

Published: May 29, 2024

Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.

Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.

Journal: Radiology

Published: April 02, 2024

Acute graft-versus-host disease associated cerebellitis as the cause of pyrexia of unknown origin detected with 18F-FDG-PET/CT.

Acute graft-versus-host disease associated cerebellitis as the cause of pyrexia of unknown origin detected with 18F-FDG-PET/CT.

Journal: Cancer treatment and research communications

Published: August 24, 2020

Ventilation perfusion lung SPECT/CT in pregnancy during COVID-19.

Ventilation perfusion lung SPECT/CT in pregnancy during COVID-19.

Journal: Internal medicine journal

Published: August 07, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026